

Unrelated Donor HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples, recipient only samples and donor only samples, Biospecimens include: whole blood, serum/plasma and limited quantities of viable cells and cell lines (collected prior to 2006), Specific inventory queries available upon request through the CIBMTR Immunobiology Research Program

Variable	Samples Available for Recipient and Donor N (%)	Samples Available for Recipient Only N (%)	Samples Available for Donor Only N (%)
Number of patients	38138	11010	7033
Source of data			
CRF	22013 (58)	5728 (52)	4263 (61)
TED	16125 (42)	5282 (48)	2770 (39)
Number of centers	250	219	318
Disease at transplant			
AML	12951 (34)	3945 (36)	2262 (32)
ALL	5630 (15)	1508 (14)	1169 (17)
Other leukemia	1320 (3)	330 (3)	226 (3)
CML	3234 (8)	870 (8)	731 (10)
MDS	6150 (16)	1965 (18)	946 (13)
Other acute leukemia	392 (1)	120 (1)	72 (1)
NHL	3598 (9)	976 (9)	578 (8)
Hodgkins Lymphoma	806 (2)	167 (2)	122 (2)
Plasma Cell Disorders, MM	769 (2)	232 (2)	111 (2)
Other malignancies	55 (<1)	13 (<1)	17 (<1)
Breast cancer	7 (<1)	3 (<1)	1 (<1)
SAA	1207 (3)	316 (3)	289 (4)
Inherited abnormalities erythrocyte diff fxn	667 (2)	189 (2)	131 (2)
SCIDs	656 (2)	193 (2)	187 (3)
Inherited abnormalities of platelets	38 (<1)	9 (<1)	9 (<1)
Inherited disorders of metabolism	263 (1)	66 (1)	81 (1)
Histiocytic disorders	334 (1)	87 (1)	76 (1)
Autoimmune disorders	16 (<1)	7 (<1)	4 (<1)
Other	45 (<1)	14 (<1)	21 (<1)
AML Disease status at transplant			
CR1	6557 (51)	2034 (52)	997 (44)
CR2	2625 (20)	784 (20)	469 (21)
CR3+	257 (2)	70 (2)	51 (2)
Advanced or active disease	3362 (26)	1015 (26)	697 (31)
Missing	146 (1)	42 (1)	44 (2)
ALL Disease status at transplant			
CR1	2675 (48)	761 (50)	476 (41)
CR2	1656 (29)	414 (27)	346 (30)
CR3+	468 (8)	119 (8)	112 (10)
Advanced or active disease	787 (14)	200 (13)	202 (17)
Missing	44 (1)	14 (1)	32 (3)
MDS Disease status at transplant			
Early	1241 (20)	333 (17)	215 (23)
Advanced	4410 (72)	1502 (77)	591 (63)
Missing	458 (7)	117 (6)	129 (14)

Refresh date: April 2019

Variable	Samples Available for Recipient and Donor N (%)	Samples Available for Recipient Only N (%)	Samples Available for Donor Only N (%)
NHL Disease status at transplant			
CR1	453 (13)	162 (17)	61 (11)
CR2	669 (19)	174 (18)	99 (17)
CR3+	305 (9)	84 (9)	48 (8)
PR	430 (12)	108 (11)	79 (14)
Advanced	1664 (47)	430 (45)	279 (49)
Missing	46 (1)	8 (1)	9 (2)
Recipient age at transplant			
0-9 years	3406 (9)	858 (8)	908 (13)
10-19 years	3534 (9)	892 (8)	834 (12)
20-29 years	4048 (11)	1118 (10)	869 (12)
30-39 years	4501 (12)	1180 (11)	907 (13)
40-49 years	5994 (16)	1688 (15)	1124 (16)
50-59 years	7951 (21)	2258 (21)	1236 (18)
60-69 years	7407 (19)	2488 (23)	1010 (14)
70+ years	1297 (3)	528 (5)	145 (2)
Median (Range)	46 (0-84)	49 (0-79)	40 (0-79)
Recipient race/ethnicity			
Caucasian, non-Hispanic	31808 (85)	9180 (85)	5286 (83)
African-American, non-Hispanic	1749 (5)	459 (4)	304 (5)
Asian, non-Hispanic	817 (2)	364 (3)	240 (4)
Pacific islander, non-Hispanic	50 (<1)	17 (<1)	14 (<1)
Native American, non-Hispanic	144 (<1)	49 (<1)	25 (<1)
Hispanic	2653 (7)	673 (6)	460 (7)
Other	44 (<1)	26 (<1)	21 (<1)
Unknown	873 (N/A)	242 (N/A)	683 (N/A)
Recipient sex			
Male	22294 (58)	6482 (59)	4159 (59)
Female	15844 (42)	4528 (41)	2874 (41)
Karnofsky score			
10-80	12605 (33)	3882 (35)	2123 (30)
90-100	24032 (63)	6567 (60)	4364 (62)
Missing	1501 (4)	561 (5)	546 (8)
HLA-A B DRB1 groups - low resolution			
<=3/6	22 (<1)	27 (<1)	1 (<1)
4/6	206 (1)	78 (1)	30 (<1)
5/6	5367 (14)	1349 (14)	995 (15)
6/6	32026 (85)	8151 (85)	5480 (84)
Unknown	517 (N/A)	1405 (N/A)	527 (N/A)
High-resolution HLA matches available out of 8			
<=5/8	837 (2)	73 (1)	28 (1)
6/8	1642 (4)	110 (2)	117 (3)
7/8	7485 (20)	1319 (18)	953 (23)
8/8	26832 (73)	5685 (79)	3078 (74)
Unknown	1342 (N/A)	3823 (N/A)	2857 (N/A)
HLA-DPB1 Match			
Double allele mismatch	8982 (30)	578 (25)	316 (28)
Single allele mismatch	16162 (54)	1200 (51)	578 (52)

Refresh date: April 2019

Variable	Samples Available for Recipient and Donor N (%)	Samples Available for Recipient Only N (%)	Samples Available for Donor Only N (%)
Full allele matched	4706 (16)	559 (24)	217 (20)
Unknown	8288 (N/A)	8673 (N/A)	5922 (N/A)
High resolution release score			
No	9627 (25)	10799 (98)	6852 (97)
Yes	28511 (75)	211 (2)	181 (3)
KIR typing available			
No	24488 (64)	10885 (99)	6992 (99)
Yes	13650 (36)	125 (1)	41 (1)
Graft type			
Marrow	14418 (38)	3874 (35)	3268 (46)
PBSC	23685 (62)	7017 (64)	3740 (53)
BM+PBSC	8 (<1)	6 (<1)	2 (<1)
BM+UCB	0	1 (<1)	0
PBSC+UCB	14 (<1)	103 (1)	1 (<1)
Others	13 (<1)	9 (<1)	22 (<1)
Conditioning regimen			
Myeloablative	24612 (65)	6761 (61)	4769 (68)
RIC/Nonmyeloablative	13352 (35)	4205 (38)	2173 (31)
TBD	174 (<1)	44 (<1)	91 (1)
Donor age at donation			
To Be Determined/NA	269 (1)	1348 (12)	86 (1)
0-9 years	12 (<1)	27 (<1)	0
10-19 years	1056 (3)	324 (3)	146 (2)
20-29 years	16475 (43)	4353 (40)	2595 (37)
30-39 years	11061 (29)	2796 (25)	2198 (31)
40-49 years	7101 (19)	1636 (15)	1519 (22)
50+ years	2164 (6)	526 (5)	489 (7)
Median (Range)	31 (0-69)	30 (0-109)	33 (18-67)
Donor/Recipient CMV serostatus			
+/+	9362 (25)	3002 (28)	1712 (26)
+/-	4569 (12)	1424 (13)	870 (13)
-/+	12467 (33)	3242 (31)	2170 (33)
-/-	11205 (30)	2924 (28)	1919 (29)
CB - recipient +	0	10 (<1)	0
CB - recipient -	1 (<1)	4 (<1)	0
CB - recipient CMV unknown	0	1 (<1)	0
Unknown	534 (N/A)	403 (N/A)	362 (N/A)
GvHD Prophylaxis			
Ex vivo T-cell depletion	1092 (3)	278 (3)	301 (4)
CD34 selection	676 (2)	297 (3)	108 (2)
Tacrolimus + MMF +- others	4549 (12)	1153 (10)	586 (8)
Tacrolimus + MTX +- others (except MMF)	16405 (43)	4882 (44)	1968 (28)
Tacrolimus + others (except MTX, MMF)	1986 (5)	702 (6)	282 (4)
Tacrolimus alone	921 (2)	299 (3)	118 (2)
CSA + MMF +- others (except Tacrolimus)	2608 (7)	594 (5)	579 (8)
CSA + MTX +- others (except Tacrolimus, MMF)	6487 (17)	1665 (15)	2156 (31)
CSA + others (except Tacrolimus, MTX, MMF)	987 (3)	299 (3)	286 (4)
CSA alone	462 (1)	116 (1)	271 (4)

Refresh date: April 2019

Variable	Samples Available for Recipient and Donor N (%)	Samples Available for Recipient Only N (%)	Samples Available for Donor Only N (%)
Other GVHD prophylaxis	695 (2)	205 (2)	116 (2)
Missing	1270 (3)	520 (5)	262 (4)
Donor/Recipient sex match			
Male-Male	15715 (41)	4350 (40)	2774 (40)
Male-Female	9548 (25)	2624 (24)	1616 (23)
Female-Male	6421 (17)	1965 (18)	1341 (19)
Female-Female	6182 (16)	1748 (16)	1228 (18)
CB - recipient M	6 (<1)	59 (1)	0
CB - recipient F	10 (<1)	52 (<1)	1 (<1)
Unknown	256 (N/A)	212 (N/A)	73 (N/A)
Year of transplant			
1986-1990	349 (1)	45 (<1)	85 (1)
1991-1995	1795 (5)	448 (4)	619 (9)
1996-2000	3150 (8)	1112 (10)	900 (13)
2001-2005	5001 (13)	988 (9)	1437 (20)
2006-2010	9198 (24)	1854 (17)	1408 (20)
2011-2015	12843 (34)	3621 (33)	1730 (25)
2016-2017	5802 (15)	2942 (27)	854 (12)
Follow-up among survivors, Months			
N Eval	16320	5103	2748
Median (Range)	56 (0-344)	36 (0-336)	51 (1-337)

Unrelated Cord Blood Transplant Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired, recipient only and cord blood only samples, Biospecimens include: whole blood, serum/plasma and limited quantities of viable cells and cell lines (collected prior to 2006-recipient only), Specific inventory queries available upon request through the CIBMTR Immunobiology Research Program

Variable	Samples Available for Recipient and Donor N (%)	Samples Available for Recipient Only N (%)	Samples Available for Donor Only N (%)
Number of patients	5277	1268	1219
Source of data			
CRF	4028 (76)	974 (77)	820 (67)
TED	1249 (24)	294 (23)	399 (33)
Number of centers	144	129	192
Disease at transplant			
AML	1972 (37)	421 (33)	395 (32)
ALL	1081 (20)	267 (21)	277 (23)
Other leukemia	91 (2)	26 (2)	23 (2)
CML	114 (2)	31 (2)	29 (2)
MDS	503 (10)	132 (10)	100 (8)
Other acute leukemia	81 (2)	19 (1)	22 (2)
NHL	369 (7)	82 (6)	82 (7)
Hodgkins Lymphoma	93 (2)	25 (2)	21 (2)
Plasma Cell Disorders, MM	34 (1)	10 (1)	6 (<1)
Other malignancies	10 (<1)	0	1 (<1)
SAA	91 (2)	29 (2)	22 (2)
Inherited abnormalities erythrocyte diff fxn	155 (3)	46 (4)	30 (2)
SCIDs	234 (4)	67 (5)	86 (7)
Inherited abnormalities of platelets	15 (<1)	3 (<1)	5 (<1)
Inherited disorders of metabolism	313 (6)	83 (7)	81 (7)
Histiocytic disorders	100 (2)	25 (2)	32 (3)
Autoimmune disorders	9 (<1)	0	1 (<1)
Other	12 (<1)	2 (<1)	6 (<1)
AML Disease status at transplant			
CR1	998 (51)	222 (53)	198 (50)
CR2	550 (28)	107 (25)	109 (28)
CR3+	50 (3)	6 (1)	12 (3)
Advanced or active disease	366 (19)	83 (20)	74 (19)
Missing	8 (<1)	2 (<1)	2 (1)
ALL Disease status at transplant			
CR1	487 (45)	112 (42)	125 (45)
CR2	406 (38)	103 (39)	101 (36)
CR3+	119 (11)	36 (13)	28 (10)
Advanced or active disease	69 (6)	16 (6)	23 (8)
MDS Disease status at transplant			
Early	161 (32)	33 (25)	46 (46)
Advanced	308 (61)	91 (70)	43 (43)
Missing	33 (7)	6 (5)	10 (10)
NHL Disease status at transplant			
CR1	56 (15)	5 (6)	17 (21)

Refresh date: April 2019

Variable	Samples Available for Recipient and Donor N (%)	Samples Available for Recipient Only N (%)	Samples Available for Donor Only N (%)
CR2	68 (19)	17 (21)	21 (26)
CR3+	42 (11)	10 (12)	9 (11)
PR	65 (18)	12 (15)	11 (14)
Advanced	135 (37)	37 (45)	22 (27)
Missing	0	1 (1)	1 (1)
Recipient age at transplant			
0-9 years	1588 (30)	468 (37)	455 (37)
10-19 years	694 (13)	144 (11)	168 (14)
20-29 years	500 (9)	89 (7)	92 (8)
30-39 years	516 (10)	109 (9)	118 (10)
40-49 years	554 (10)	127 (10)	111 (9)
50-59 years	739 (14)	154 (12)	145 (12)
60-69 years	602 (11)	155 (12)	121 (10)
70+ years	84 (2)	22 (2)	9 (1)
Median (Range)	27 (0-81)	23 (0-75)	19 (0-78)
Recipient race/ethnicity			
Caucasian, non-Hispanic	2937 (59)	758 (63)	673 (62)
African-American, non-Hispanic	758 (15)	171 (14)	139 (13)
Asian, non-Hispanic	305 (6)	74 (6)	78 (7)
Pacific islander, non-Hispanic	25 (<1)	3 (<1)	13 (1)
Native American, non-Hispanic	34 (1)	6 (<1)	13 (1)
Hispanic	957 (19)	194 (16)	172 (16)
Other	0	1 (<1)	1 (<1)
Unknown	261 (N/A)	61 (N/A)	130 (N/A)
Recipient sex			
Male	2901 (55)	731 (58)	699 (57)
Female	2376 (45)	537 (42)	520 (43)
Karnofsky score			
10-80	1352 (26)	309 (24)	292 (24)
90-100	3782 (72)	873 (69)	853 (70)
Missing	143 (3)	86 (7)	74 (6)
HLA-A B DRB1 groups - low resolution			
<=3/6	71 (1)	29 (3)	6 (1)
4/6	2072 (41)	406 (41)	422 (38)
5/6	2260 (45)	409 (42)	534 (47)
6/6	642 (13)	137 (14)	163 (14)
Unknown	232 (N/A)	287 (N/A)	94 (N/A)
High-resolution HLA matches available out of 8			
<=5/8	2500 (56)	419 (58)	484 (54)
6/8	1082 (24)	162 (22)	215 (24)
7/8	603 (13)	91 (13)	130 (14)
8/8	297 (7)	49 (7)	69 (8)
Unknown	795 (N/A)	547 (N/A)	321 (N/A)
HLA-DPB1 Match			
Double allele mismatch	696 (40)	45 (43)	42 (37)
Single allele mismatch	866 (50)	49 (47)	59 (52)
Full allele matched	162 (9)	10 (10)	12 (11)
Unknown	3553 (N/A)	1164 (N/A)	1106 (N/A)

Refresh date: April 2019

Variable	Samples Available for Recipient and Donor N (%)	Samples Available for Recipient Only N (%)	Samples Available for Donor Only N (%)
High resolution release score			
No	3781 (72)	1218 (96)	1208 (99)
Yes	1496 (28)	50 (4)	11 (1)
KIR typing available			
No	4015 (76)	1262 (>99)	1209 (99)
Yes	1262 (24)	6 (<1)	10 (1)
Graft type			
UCB	4992 (95)	1164 (92)	1160 (95)
BM+UCB	1 (<1)	1 (<1)	0
PBSC+UCB	256 (5)	103 (8)	52 (4)
Others	28 (1)	0	7 (1)
Number of cord units			
1	4425 (84)	0	1019 (84)
2	850 (16)	0	200 (16)
3	2 (<1)	0	0
Unknown	0 (N/A)	1268 (N/A)	0 (N/A)
Conditioning regimen			
Myeloablative	3479 (66)	824 (65)	798 (65)
RIC/Nonmyeloablative	1788 (34)	441 (35)	417 (34)
TBD	10 (<1)	3 (<1)	4 (<1)
Donor age at donation			
To Be Determined/NA	142 (3)	80 (6)	77 (6)
0-9 years	4702 (89)	999 (79)	1057 (87)
10-19 years	278 (5)	110 (9)	52 (4)
20-29 years	45 (1)	22 (2)	7 (1)
30-39 years	46 (1)	27 (2)	12 (1)
40-49 years	27 (1)	12 (1)	4 (<1)
50+ years	37 (1)	18 (1)	10 (1)
Median (Range)	4 (0-72)	4 (0-73)	3 (0-67)
Donor/Recipient CMV serostatus			
+/+	1221 (23)	257 (20)	251 (21)
+/-	536 (10)	121 (10)	114 (9)
-/+	984 (19)	231 (18)	222 (18)
-/-	657 (12)	159 (13)	171 (14)
CB - recipient +	1070 (20)	262 (21)	228 (19)
CB - recipient -	726 (14)	190 (15)	188 (15)
CB - recipient CMV unknown	83 (2)	48 (4)	45 (4)
GvHD Prophylaxis			
Ex vivo T-cell depletion	29 (1)	9 (1)	4 (<1)
CD34 selection	188 (4)	79 (6)	39 (3)
Tacrolimus + MMF +- others	1410 (27)	318 (25)	190 (16)
Tacrolimus + MTX +- others (except MMF)	200 (4)	55 (4)	57 (5)
Tacrolimus + others (except MTX, MMF)	215 (4)	54 (4)	48 (4)
Tacrolimus alone	132 (3)	43 (3)	23 (2)
CSA + MMF +- others (except Tacrolimus)	2486 (47)	531 (42)	606 (50)
CSA + MTX +- others (except Tacrolimus, MMF)	93 (2)	27 (2)	38 (3)
CSA + others (except Tacrolimus, MTX, MMF)	310 (6)	106 (8)	139 (11)
CSA alone	56 (1)	17 (1)	44 (4)

Refresh date: April 2019

Variable	Samples Available for Recipient and Donor N (%)	Samples Available for Recipient Only N (%)	Samples Available for Donor Only N (%)
Other GVHD prophylaxis	125 (2)	16 (1)	17 (1)
Missing	33 (1)	13 (1)	14 (1)
Donor/Recipient sex match			
CB - recipient M	2901 (55)	731 (58)	698 (57)
CB - recipient F	2376 (45)	537 (42)	520 (43)
CB - recipient sex unknown	0	0	1 (<1)
Year of transplant			
1996-2000	0	2 (<1)	4 (<1)
2001-2005	106 (2)	82 (6)	29 (2)
2006-2010	1776 (34)	409 (32)	432 (35)
2011-2015	2574 (49)	495 (39)	574 (47)
2016-2017	821 (16)	280 (22)	180 (15)
Follow-up among survivors, Months			
N Eval	2560	683	629
Median (Range)	53 (1-150)	37 (2-191)	49 (1-217)

Related Donor HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired, recipient only and donor only samples, Biospecimens include: whole blood, serum/plasma and limited quantities of viable cells and cell lines (collected prior to 2006), Specific inventory queries available upon request through the CIBMTR Immunobiology Research Program

Variable	Samples Available for Recipient and Donor N (%)	Samples Available for Recipient Only N (%)	Samples Available for Donor Only N (%)
Number of patients	6330	956	437
Source of data			
CRF	2414 (38)	293 (31)	179 (41)
TED	3916 (62)	663 (69)	258 (59)
Number of centers	83	65	53
Disease at transplant			
AML	2065 (33)	323 (34)	129 (30)
ALL	1005 (16)	182 (19)	68 (16)
Other leukemia	144 (2)	27 (3)	20 (5)
CML	218 (3)	20 (2)	12 (3)
MDS	1045 (17)	151 (16)	69 (16)
Other acute leukemia	85 (1)	14 (1)	3 (1)
NHL	640 (10)	89 (9)	61 (14)
Hodgkins Lymphoma	135 (2)	20 (2)	21 (5)
Plasma Cell Disorders, MM	191 (3)	29 (3)	17 (4)
Other malignancies	17 (<1)	0	0
Breast cancer	1 (<1)	0	0
SAA	281 (4)	33 (3)	12 (3)
Inherited abnormalities erythrocyte diff fxn	311 (5)	42 (4)	15 (3)
SCIDs	125 (2)	20 (2)	7 (2)
Inherited abnormalities of platelets	9 (<1)	0	0
Inherited disorders of metabolism	9 (<1)	0	0
Histiocytic disorders	31 (<1)	4 (<1)	2 (<1)
Autoimmune disorders	6 (<1)	0	0
Other	12 (<1)	2 (<1)	1 (<1)
AML Disease status at transplant			
CR1	1271 (62)	207 (64)	82 (64)
CR2	325 (16)	37 (11)	12 (9)
CR3+	24 (1)	4 (1)	0
Advanced or active disease	437 (21)	73 (23)	33 (26)
Missing	8 (<1)	2 (1)	2 (2)
ALL Disease status at transplant			
CR1	628 (62)	113 (62)	49 (72)
CR2	277 (28)	40 (22)	11 (16)
CR3+	42 (4)	9 (5)	3 (4)
Advanced or active disease	58 (6)	20 (11)	5 (7)
MDS Disease status at transplant			
Early	182 (17)	20 (13)	9 (13)
Advanced	831 (80)	127 (84)	58 (84)
Missing	32 (3)	4 (3)	2 (3)
NHL Disease status at transplant			

Refresh date: April 2019

Variable	Samples Available for Recipient and Donor N (%)	Samples Available for Recipient Only N (%)	Samples Available for Donor Only N (%)
CR1	104 (16)	21 (24)	11 (18)
CR2	126 (20)	15 (17)	11 (18)
CR3+	71 (11)	7 (8)	2 (3)
PR	58 (9)	11 (13)	6 (10)
Advanced	277 (44)	33 (38)	31 (51)
Recipient age at transplant			
0-9 years	602 (10)	76 (8)	27 (6)
10-19 years	680 (11)	73 (8)	28 (6)
20-29 years	517 (8)	99 (10)	39 (9)
30-39 years	484 (8)	85 (9)	35 (8)
40-49 years	865 (14)	129 (13)	62 (14)
50-59 years	1508 (24)	218 (23)	112 (26)
60-69 years	1468 (23)	244 (26)	123 (28)
70+ years	206 (3)	32 (3)	11 (3)
Median (Range)	50 (0-78)	51 (0-76)	53 (0-74)
Recipient race/ethnicity			
Caucasian, non-Hispanic	4075 (67)	517 (58)	289 (68)
African-American, non-Hispanic	727 (12)	97 (11)	43 (10)
Asian, non-Hispanic	285 (5)	82 (9)	23 (5)
Pacific islander, non-Hispanic	24 (<1)	3 (<1)	0
Native American, non-Hispanic	23 (<1)	1 (<1)	0
Hispanic	954 (16)	197 (22)	67 (16)
Unknown	242 (N/A)	59 (N/A)	15 (N/A)
Recipient sex			
Male	3716 (59)	577 (60)	253 (58)
Female	2614 (41)	379 (40)	184 (42)
Karnofsky score			
10-80	2191 (35)	390 (41)	183 (42)
90-100	3989 (63)	540 (56)	234 (54)
Missing	150 (2)	26 (3)	20 (5)
Graft type			
Marrow	1769 (28)	227 (24)	122 (28)
PBSC	4521 (71)	718 (75)	311 (71)
BM+PBSC	6 (<1)	3 (<1)	0
BM+UCB	19 (<1)	5 (1)	1 (<1)
PBSC+UCB	0	0	3 (1)
Others	15 (<1)	3 (<1)	0
Conditioning regimen			
Myeloablative	3693 (58)	548 (57)	232 (53)
RIC/Nonmyeloablative	2603 (41)	402 (42)	199 (46)
TBD	34 (1)	6 (1)	6 (1)
Donor age at donation			
To Be Determined/NA	20 (<1)	4 (<1)	3 (1)
0-9 years	429 (7)	44 (5)	18 (4)
10-19 years	614 (10)	86 (9)	29 (7)
20-29 years	780 (12)	128 (13)	51 (12)
30-39 years	794 (13)	142 (15)	72 (16)
40-49 years	1039 (16)	160 (17)	62 (14)

Refresh date: April 2019

Variable	Samples Available for Recipient and Donor N (%)	Samples Available for Recipient Only N (%)	Samples Available for Donor Only N (%)
50+ years	2654 (42)	392 (41)	202 (46)
Median (Range)	46 (0-81)	45 (0-79)	47 (0-76)
Donor/Recipient CMV serostatus			
+/+	2566 (41)	460 (49)	190 (45)
+/-	688 (11)	67 (7)	50 (12)
-/+	1565 (25)	220 (23)	95 (23)
-/-	1423 (23)	190 (20)	86 (20)
Unknown	88 (N/A)	19 (N/A)	16 (N/A)
GvHD Prophylaxis			
Ex vivo T-cell depletion	79 (1)	21 (2)	3 (1)
CD34 selection	90 (1)	28 (3)	7 (2)
Tacrolimus + MMF +- others	709 (11)	63 (7)	27 (6)
Tacrolimus + MTX +- others (except MMF)	2624 (41)	346 (36)	209 (48)
Tacrolimus + others (except MTX, MMF)	568 (9)	202 (21)	47 (11)
Tacrolimus alone	51 (1)	6 (1)	2 (<1)
CSA + MMF +- others (except Tacrolimus)	169 (3)	14 (1)	5 (1)
CSA + MTX +- others (except Tacrolimus, MMF)	516 (8)	58 (6)	26 (6)
CSA + others (except Tacrolimus, MTX, MMF)	61 (1)	10 (1)	2 (<1)
CSA alone	57 (1)	8 (1)	2 (<1)
Other GVHD prophylaxis	96 (2)	9 (1)	6 (1)
Missing	1310 (21)	191 (20)	101 (23)
Donor/Recipient sex match			
Male-Male	2054 (32)	351 (37)	149 (34)
Male-Female	1368 (22)	178 (19)	86 (20)
Female-Male	1643 (26)	219 (23)	103 (24)
Female-Female	1242 (20)	199 (21)	95 (22)
CB - recipient M	15 (<1)	6 (1)	1 (<1)
CB - recipient F	4 (<1)	2 (<1)	3 (1)
Unknown	4 (N/A)	1 (N/A)	0 (N/A)
Year of transplant			
2006-2010	518 (8)	49 (5)	39 (9)
2011-2015	3265 (52)	459 (48)	210 (48)
2016-2017	2547 (40)	448 (47)	188 (43)
Follow-up among survivors, Months			
N Eval	4031	606	275
Median (Range)	25 (1-126)	24 (3-121)	25 (2-123)